SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(McGinnis R)
 

Search: WFRF:(McGinnis R) > The largest prospec...

The largest prospective warfarin-treated cohort supports genetic forecasting

Wadelius, Mia (author)
Uppsala universitet,Klinisk farmakogenomik och osteoporos
Chen, Leslie Y. (author)
Lindh, Jonatan D. (author)
Karolinska Institutet
show more...
Eriksson, Niclas (author)
Uppsala universitet,Klinisk farmakologi
Ghori, Mohammed J. R. (author)
Bumpstead, Suzannah (author)
Holm, Lennart (author)
McGinnis, Ralph (author)
Rane, Anders (author)
Karolinska Institutet
Deloukas, Panos (author)
show less...
 (creator_code:org_t)
American Society of Hematology, 2009
2009
English.
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 113:4, s. 784-792
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose, but the effect of other genes has not been fully elucidated. We genotyped 183 polymorphisms in 29 candidate genes in 1496 Swedish patients starting warfarin treatment, and tested for association with response. CYP2C9*2 and *3 explained 12% (P = 6.63 x 10(-34)) of the variation in warfarin dose, while a single VKORC1 SNP explained 30% (P = 9.82 x 10(-100)). No SNP outside the CYP2C gene cluster and VKORC1 regions was significantly associated with dose after correction for multiple testing. During initiation of therapy, homozygosity for CYP2C9 and VKORC1 variant alleles increased the risk of over-anticoagulation, hazard ratios 21.84 (95% CI 9.46; 50.42) and 4.56 (95% CI 2.85; 7.30), respectively. One of 8 patients with CYP2C9*3/*3 (12.5%) experienced severe bleeding during the first month compared with 0.27% of other patients (P = .066). A multiple regression model using the predictors CYP2C9, VKORC1, age, sex, and druginteractions explained 59% of the variance in warfarin dose, and 53% in an independent sample of 181 Swedish individuals. In conclusion, CYP2C9 and VKORC1 significantly influenced warfarin dose and predicted individuals predisposed to unstable anticoagulation. Our results strongly support that initiation of warfarin guided by pharmacogenetics would improve clinical outcome.

Keyword

MEDICINE
MEDICIN

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view